The US NIH awards Advaxis $210,000 for the development of dual
1 September 2009
Advaxis (OTCBB: ADXS) has been awarded a $210,000 grant
from the US National Institutes of Health (NIH) to develop a single
bioengineered Listeria monocytogenes (Lm) vaccine to
deliver two different antigen-adjuvant proteins.
This technology enables a single vaccine to simultaneously attack two
separate and distinct tumour targets with a higher level of potency.
Further investigational work by is focusing on the use of this dual
delivery approach directed against a tumour cell surface marker to kill
tumour cells directly plus an anti-angiogenic target that would impair a
tumour's ability to grow by simultaneously reducing its blood supply.
“Advaxis continues to invent new ways to use the very powerful live
Listeria vaccine platform to treat disease,” commented Advaxis CEO
Thomas A. Moore. “The remarkably broad and effective immune response to
Listeria vaccines enables us to work with a wide variety of different
antigens in order to maximize their efficacy; and now we can work with
more than one antigen at a time.”
Bookmark this page